BioPharma Resources

Drug Trial Radar · NCT03338621

Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 455 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

455

Actual

Start

Jul 30, 2018

Primary completion

Jul 1, 2021

Study completion Jun 10, 2022

Sponsor

Lead sponsor
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients given BPaMZ for 17 Weeks ( or 4 months) vs. Standard HRZE/HR treatment given for 26 weeks (or 6 months) and Drug Resistant TB (DR-TB) patients given BPaMZ for 26 Weeks (or 6 months)

Conditions

  • Tuberculosis, Pulmonary
  • Tuberculosis, Multidrug-Resistant
  • Tuberculosis, MDR
  • Tuberculosis
  • Drug-Resistant Tuberculosis

Interventions

  • PretomanidDrug

    200 mg tablets

  • BedaquilineDrug

    100 mg tablets

  • MoxifloxacinDrug

    400 mg tablets

  • PyrazinamideDrug

    500 mg tablets

  • HRZEDrug

    isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets

  • HRDrug

    isoniazid 75 mg plus rifampicin 150 mg combination tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Culture Negative Status by 8 WeeksTime frame: Days 0-56 (8 weeks)

Locations

26 sites in 8 countries. Site status is shown where the registry gives one.

  • Evandro Chagas

    Rio de Janeiro, Brazil

  • FIOCRUZ

    Rio de Janeiro, Brazil

  • National Center for Tuberculosis and Lung Diseases

    Tbilisi, K'alak'i T'bilisi, Georgia

  • Institut Perubatan Respiratori

    Kuala Lumpur, Malaysia

  • Lung Center of Philippines

    Manila, Philippines

  • Tropical Disease Foundation

    Manila, Philippines

  • Moscow City Research and Practice Tuberculosis Treatment Centre

    Moscow, Russia

  • Central TB Research Institute of the Federal Agency of Scientific Organizations

    Moscow, Russia

  • Research Institute of Phthisiopulmonology of I. M. Sechenov First Moscow State Medical University

    Moscow, Russia

  • Research Institute of the Phthisiopulmonology

    Saint Petersburg, Russia

  • Ural Research Institute of Phthisiopulmonology

    Yekaterinburg, Russia

  • Madibeng Centre for Research

    Brits, South Africa

  • TASK

    Cape Town, South Africa

  • University of Cape Town Lung Institute

    Cape Town, South Africa

  • Enhancing Care Foundation

    Durban, South Africa

  • CHRU, King Dinuzulu

    Durban, South Africa

  • CHRU, Helen Joseph Hospital

    Johannesburg, South Africa

  • PHRU, Tshepong Hospital

    Klerksdorp, South Africa

  • CHRU, Empilweni TB Hospital

    Port Elizabeth, South Africa

  • Setshaba Research Centre

    Soshanguve, South Africa

  • THINK

    Pietermaritzburg, KwaZulu-Natal, South Africa

  • Ifakara Health Institute

    Bagamoyo, Tanzania

  • NIMR-Mbeya

    Mbeya, Tanzania

  • Kilimanjaro Clinical Research Institute

    Moshi, Tanzania

  • Mwanza Intervention Trials Unit

    Mwanza, Tanzania, Tanzania

  • Case Western Reserve University

    Kampala, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.